$358 Million is the total value of Affinity Asset Advisors, LLC's 64 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 281.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $89,295,000 | – | 250,000 | +100.0% | 24.92% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $12,939,000 | – | 190,000 | +100.0% | 3.61% | – |
| IWM | New | ISHARES TRput | $11,544,000 | – | 70,000 | +100.0% | 3.22% | – |
| SNY | New | SANOFIsponsored adr | $11,406,000 | – | 300,000 | +100.0% | 3.18% | – |
| SNY | New | SANOFIput | $9,505,000 | – | 250,000 | +100.0% | 2.65% | – |
| AZN | Buy | ASTRAZENECA PLCsponsored adr | $8,226,000 | +46.5% | 150,000 | +76.5% | 2.30% | -3.0% |
| New | VENTYX BIOSCIENCES INC | $5,935,000 | – | 170,000 | +100.0% | 1.66% | – | |
| PNT | Buy | POINT BIOPHARMA GLOBAL INC | $5,771,000 | +3216.7% | 746,576 | +2818.8% | 1.61% | +2106.8% |
| AZN | New | ASTRAZENECA PLCput | $5,484,000 | – | 100,000 | +100.0% | 1.53% | – |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $4,993,000 | – | 175,000 | +100.0% | 1.39% | – |
| MDGL | New | MADRIGAL PHARMACEUTICALS INCput | $4,874,000 | – | 75,000 | +100.0% | 1.36% | – |
| PEN | New | PENUMBRA INCcall | $4,740,000 | – | 25,000 | +100.0% | 1.32% | – |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $4,274,000 | +24.0% | 267,794 | +6.9% | 1.19% | -17.9% |
| Buy | ARCELLX INC | $3,944,000 | +190.9% | 210,138 | +180.2% | 1.10% | +92.5% | |
| ZNTL | Buy | ZENTALIS PHARMACEUTICALS INC | $3,682,000 | +87.2% | 170,000 | +142.9% | 1.03% | +24.0% |
| New | ASTRIA THERAPEUTICS INC | $3,616,000 | – | 400,043 | +100.0% | 1.01% | – | |
| VRNA | New | VERONA PHARMA PLCsponsored adr | $3,577,000 | – | 350,000 | +100.0% | 1.00% | – |
| New | GSK PLCput | $3,237,000 | – | 110,000 | +100.0% | 0.90% | – | |
| CYTK | Buy | CYTOKINETICS INC | $3,149,000 | +434.6% | 65,000 | +333.3% | 0.88% | +254.4% |
| COGT | Buy | COGENT BIOSCIENCES INC | $2,299,000 | +103.8% | 154,087 | +23.3% | 0.64% | +35.2% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $2,249,000 | +108.6% | 80,000 | +100.0% | 0.63% | +38.3% |
| New | GSK PLCsponsored adr | $2,207,000 | – | 75,000 | +100.0% | 0.62% | – | |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $2,147,000 | +53.8% | 136,434 | +36.4% | 0.60% | +1.9% |
| VINC | Buy | VINCERX PHARMA INC | $2,060,000 | +13.6% | 1,492,771 | +8.6% | 0.58% | -24.8% |
| FXE | New | INVESCO CURRENCYSHARES EUROput | $1,809,000 | – | 20,000 | +100.0% | 0.50% | – |
| VRNA | New | VERONA PHARMA PLCput | $1,687,000 | – | 165,100 | +100.0% | 0.47% | – |
| GERN | New | GERON CORPput | $1,521,000 | – | 650,000 | +100.0% | 0.42% | – |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $1,475,000 | – | 25,000 | +100.0% | 0.41% | – |
| GERN | New | GERON CORPcall | $1,465,000 | – | 626,000 | +100.0% | 0.41% | – |
| New | PRECIGEN INCnote 3.500% 7/0 | $1,455,000 | – | 1,500,000 | +100.0% | 0.41% | – | |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $1,398,000 | – | 96,318 | +100.0% | 0.39% | – |
| MIST | New | MILESTONE PHARMACEUTICALS INcall | $1,261,000 | – | 137,200 | +100.0% | 0.35% | – |
| Buy | LIANBIOsponsored ads | $1,095,000 | +12.7% | 550,000 | +22.2% | 0.31% | -25.4% | |
| FXB | New | INVESCO CURRENCYSHARES BRITput | $1,073,000 | – | 10,000 | +100.0% | 0.30% | – |
| CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $975,000 | – | 242,517 | +100.0% | 0.27% | – |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $792,000 | – | 110,000 | +100.0% | 0.22% | – |
| VERV | New | VERVE THERAPEUTICS INCcall | $687,000 | – | 20,000 | +100.0% | 0.19% | – |
| VKTX | New | VIKING THERAPEUTICS INC | $680,000 | – | 250,000 | +100.0% | 0.19% | – |
| ISEE | New | IVERIC BIO INCcall | $538,000 | – | 30,000 | +100.0% | 0.15% | – |
| KURA | New | KURA ONCOLOGY INCput | $507,000 | – | 37,100 | +100.0% | 0.14% | – |
| New | TANGO THERAPEUTICS INC | $297,000 | – | 81,982 | +100.0% | 0.08% | – | |
| VCKAW | New | VICKERS VANTAGE CORP I*w exp 09/15/202 | $17,000 | – | 100,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-07 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.